20 articles
A major review reveals how inflammaging and immunosenescence synergistically drive colorectal cancer in older adults, reshaping the tumor microenvironment.
A sweeping 2025 review maps how gut, tumor, and systemic microbiomes promote or suppress cancer across every major tumor type.
New research reveals young and elderly cervical cancer patients have completely different molecular signatures requiring age-specific treatments.
Large study reveals cancer survivors have higher biological age than cancer-free individuals, with strongest mortality predictions from epigenetic clocks.
New research reveals how a common gut bacterium reprograms immune cells to accelerate colorectal cancer progression.
Machine learning models achieve 88-97% accuracy in detecting gastric cancer risk through microbiome analysis, opening new paths for early detection.
Researchers propose guidelines to study how microbes within tumors influence cancer progression and treatment responses.
Scientists discover how two microbes team up to accelerate colon cancer, but L-arginine may disrupt their deadly partnership.
Study identifies senescent EGR1+ B cells that sabotage immunotherapy in esophageal cancer, with fisetin showing promise as a therapeutic enhancer.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
Researchers developed rat and mouse models mimicking early and middle stages of oral submucous fibrosis using bleomycin injections.
A cancer patient on nivolumab developed Eikenella corrodens bacteremia after CNS infection, revealing how immune checkpoint therapy may enable dangerous microbial dissemination.
Specific gut bacteria enhance anti-PD-1 cancer treatment by converting immune cells into powerful tumor fighters.
Specific bacterial metabolic pathways in the gut determine whether cancer immunotherapy works by controlling immune responses.
Specific gut microbes produce compounds that reprogram fat cells to enhance immune responses against cancer.
New research reveals how tiny cellular packages from aging cells might be engineered to deliver targeted cancer treatments.
New research reveals how selenium deficiency drives liver cancer progression through neutrophil aging and immune suppression.
Pre-treatment gut microbiome signatures predicted cancer recurrence in 674 melanoma patients receiving immune checkpoint blockade, with AUC up to 0.94.
Engineered magnetotactic bacteria delivered orally penetrate colorectal tumors, trigger immune attack, and reshape gut microbial metabolism in mice.
A gut metabolite produced after chemo reprograms bone marrow immune cells, creating a lasting shield against colorectal cancer liver metastasis.
